Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00747539 · ClinicalTrials.gov registry record

Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy

A clinical trial of HIV and Hepatitis C, sponsored by University of California, Los Angeles.

Completed
Registry status
330
Enrollment target
4
Study locations

NCT00747539: Completed study of HIV and Hepatitis C, sponsored by University of California, Los Angeles.

NCT00747539 is a study of HIV and Hepatitis C that has completed, run by University of California, Los Angeles. The registered enrollment target is 330 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (25% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00747539, a study of HIV and Hepatitis C, has completed, sponsored by University of California, Los Angeles.

COMPLETED
Registry status
330 participants
Enrollment target
4
Study locations

Study Summary

This study will evaluate the impact of standard hepatitis C virus treatment on brain deficits in people who are infected with both HIV and the hepatitis C virus.

Interventions

  • DRUG Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)

Study Locations (4)

California

  • Kaiser Permanente Infectious Diseases, Antelope Valley - Lancaster
  • University of California, Los Angeles, School of Medicine - Los Angeles
  • AIDS Healthcare Foundation - Los Angeles
  • Veterans Administration Greater Los Angeles Healthcare System - Los Angeles

Trial Details

FieldValue
Enrollment Target 330 participants
Start Date 2008-07
Est. Completion 2015-06

What the finished NCT00747539 record still lists

NCT00747539 is an observational study that tracks outcomes without assigning an intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap, below the 439-participant average among 303 other HIV trials with a reported enrollment target (25% lower).

The record links to 3 conditions, with HIV appearing as the primary indexed condition, and to 1 intervention - of which Pegylated interferon alfa and ribavirin (PEG-IFN/RBV) is the first listed.

NCT00747539 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00747539 about?

NCT00747539 is a clinical study titled "Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy". This study will evaluate the impact of standard hepatitis C virus treatment on brain deficits in people who are infected with both HIV and the hepatitis C virus.

What is the current status of trial NCT00747539?

This trial is currently completed. The enrollment target is 330 participants. The study started on 2008-07. Estimated completion is 2015-06.

What conditions does trial NCT00747539 study?

This clinical trial studies the following conditions: HIV, Hepatitis C, Infections.

What interventions are being tested in trial NCT00747539?

The interventions under investigation include: Pegylated interferon alfa and ribavirin (PEG-IFN/RBV) (DRUG).

Who is sponsoring clinical trial NCT00747539?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00747539 being conducted?

This trial has 4 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00747539's enrollment target sits among peer trials

330 62nd of 303 higher than 241 of 303 other HIV trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00359684 · 330 participants

    Use of Cysteamine in the Treatment of Cystinosis

  • NCT03817502 · 330 participants · Phase 3

    Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

  • NCT03922724 · 330 participants · Phase 2

    Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

  • NCT03932773 · 330 participants · NA

    Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00747539, the US trial registry maintained by the National Library of Medicine. NCT00747539 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.